240 related articles for article (PubMed ID: 11235922)
1. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
Lesem MD; Zajecka JM; Swift RH; Reeves KR; Harrigan EP
J Clin Psychiatry; 2001 Jan; 62(1):12-8. PubMed ID: 11235922
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP
Psychopharmacology (Berl); 2001 May; 155(2):128-34. PubMed ID: 11401000
[TBL] [Abstract][Full Text] [Related]
3. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
Mendelowitz AJ
Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.
Barak Y; Mazeh D; Plopski I; Baruch Y
Am J Geriatr Psychiatry; 2006 Jul; 14(7):629-33. PubMed ID: 16816018
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
Brook S; Lucey JV; Gunn KP
J Clin Psychiatry; 2000 Dec; 61(12):933-41. PubMed ID: 11206599
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
Brook S
J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
[TBL] [Abstract][Full Text] [Related]
7. Best clinical practice with ziprasidone IM: update after 2 years of experience.
Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
[TBL] [Abstract][Full Text] [Related]
8. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.
Daniel DG; Zimbroff DL; Swift RH; Harrigan EP
Int Clin Psychopharmacol; 2004 Jan; 19(1):9-15. PubMed ID: 15101564
[TBL] [Abstract][Full Text] [Related]
9. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Kohen I; Preval H; Southard R; Francis A
Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
[TBL] [Abstract][Full Text] [Related]
11. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
12. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
13. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders.
Agid O; Kapur S; Warrington L; Loebel A; Siu C
Schizophr Res; 2008 Jul; 102(1-3):241-8. PubMed ID: 18495436
[TBL] [Abstract][Full Text] [Related]
14. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.
Baldaçara L; Sanches M; Cordeiro DC; Jackoswski AP
Braz J Psychiatry; 2011 Mar; 33(1):30-9. PubMed ID: 21537720
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular ziprasidone in youth: a retrospective chart review.
Staller JA
J Child Adolesc Psychopharmacol; 2004; 14(4):590-2. PubMed ID: 15662151
[TBL] [Abstract][Full Text] [Related]
16. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
17. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial.
Mautone A; Scarone S;
Pharmacopsychiatry; 2011 Jul; 44(5):173-8. PubMed ID: 21751127
[TBL] [Abstract][Full Text] [Related]
18. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
19. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Zhang H; Wang G; Zhao J; Xie S; Xu X; Shi J; Deng H; Li K; Gao C; Wang X; Vanderburg D; Pan S; Tang H; Shu L; Karayal ON
J Clin Psychopharmacol; 2013 Apr; 33(2):178-85. PubMed ID: 23422376
[TBL] [Abstract][Full Text] [Related]
20. Injectable atypical antipsychotics for agitation in borderline personality disorder.
Pascual JC; Madre M; Soler J; Barrachina J; Campins MJ; Alvarez E; Pérez V
Pharmacopsychiatry; 2006 May; 39(3):117-8. PubMed ID: 16721704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
